The manufacturer of finerenone is Bayer [1]. Finerenone is marketed under the brand name Kerendia [2].
What is Kerendia used for?
Kerendia is a medication used to treat adults with chronic kidney disease (CKD) associated with type 2 diabetes [3]. It works by reducing the risk of kidney-related events, such as kidney failure, and cardiovascular events, such as heart attack or stroke [4].
How does finerenone work?
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist [4]. It works by blocking the harmful effects of excess mineralocorticoid receptor stimulation in the kidneys and cardiovascular system, which are often exacerbated by diabetes [5]. This action helps to reduce inflammation and fibrosis, thereby protecting the organs [5].
What are the key clinical trials for finerenone?
The efficacy and safety of finerenone have been established in major clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies [3][6]. These trials demonstrated that finerenone significantly reduced the risk of key kidney and cardiovascular outcomes in patients with CKD and type 2 diabetes [3][6].
When does finerenone's patent expire?
Drug patent information can be complex and vary by region. Information on the specific patent expiry dates for finerenone can be found through resources like DrugPatentWatch.com [7].
Are there any generic versions of finerenone available or expected?
As of now, finerenone is a branded medication manufactured by Bayer. The availability of generic versions would depend on patent expiry and regulatory approvals.
What are the potential side effects of finerenone?
Common side effects of finerenone include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [3]. Regular monitoring of potassium levels and kidney function is recommended during treatment [3].